Summary
Patent 7,141,593, granted to Genentech, Inc., covers an anti-CD20 antibody related to Rituximab, a pioneering monoclonal antibody used in treatments for B-cell lymphomas, rheumatoid arthritis, and other autoimmune diseases. This comprehensive review details the scope of the claims, patent landscape, and relevant legal and scientific context as of 2023. It provides a strategic understanding for stakeholders involved in biosimilar development, licensing negotiations, or patent litigation.

Scope of Patent 7,141,593

What are the core claims of U.S. Patent 7,141,593?

The patent primarily claims the following:

Claim Number	Type	Scope	Summary
Claims 1-4	Independent	Antibodies	Monoclonal antibodies with specific sequences or binding characteristics targeting CD20. They specify certain heavy and light chain variable region sequences, complementarity-determining regions (CDRs), and binding affinities.
Claims 5-8	Dependent	Specific MAbs	Modified or isoform variants of the core antibody with variants in CDR sequences, glycosylation, or other post-translational modifications.
Claims 9-12	Dependent	Uses & Methods	Methods of using the antibody for treating diseases, including administering in specific doses or combinations.

Key Elements of the Claims

Sequence-specific Claims: The claims specify amino acid sequences of the variable regions of the heavy (VH) and light (VL) chains, with sequence identifiers such as SEQ ID NOs.
Binding Characteristics: The antibodies possess high affinity for CD20, with particular binding constants, e.g., K_D in the nanomolar range.
Functional Activity: The claims encompass mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Therapeutic Use: The patent explicitly claims methods for treating B-cell related disorders, notably non-Hodgkin’s lymphoma and rheumatoid arthritis.

Scope Limitations

The claims are limited to antibodies with the specified amino acid sequences and binding properties.
Variants deviating from the initial sequences without explicit language are outside the scope.
Use claims encompass only specific methods of treatment, not broader indications.

Patent Landscape of Anti-CD20 Monoclonal Antibodies

Major Patent Families and Related Patents

Patent Family/Patent	Issuer/Applicants	Focus	Key Patent Numbers	Relevant Dates
Genentech's Anti-CD20 Patents	Genentech, Inc.	Rituximab (Chimeric MAb)	US 7,141,593; US 6,914,126; US 5,736,137	2008, 2004, 1998
Celltech/UK Patents	Celltech	Humanized Anti-CD20 antibodies	WO 02031589	2002
Roche Patents	Roche	Biosimilar/second-generation anti-CD20	WO 2012/056363	2012

Key Patent Statutes and Periods

Aspect	Details
Priority Date	August 28, 1998 (filing date for the original application)
Term Expiry	20 years from priority date — approximately August 28, 2018 (adjusted by PTA)
Patent Term Adjustments	Patent term adjustments extend patent life, with particular scrutiny on USPTO rulings.

Legal Status and Litigation

No significant litigations related specifically to US 7,141,593 have been publicly documented post-grant.
Patent exclusivity considerations remain relevant until at least 2018, although extensions and patent term adjustments may affect effective rights.

Key Technical and Legal Insights

Sequence and Binding Specificity

The patent's claims margin on the specific amino acid sequences of variable regions confers narrow scope but provides undoubted protection for antibodies closely matching the claimed sequences.
Key CDR sequences (e.g., SEQ ID NOs) are critical for establishing infringement.

Innovation and Filing Strategy

The patent's filing in 1998 aligns with the first therapeutic approvals and research, conferring early priority.
The drafted claims focus on specific sequence variants, preserving rights against generic versions that diverge significantly.

Comparable Technologies

Competitor Patents	Focus	Filing Date	Relation to 7,141,593
Genentech's Continuation Applications	Broader claims on antibody constructs	2004-2006	Expanding scope, possibly overlapping
Roche's Filing for Biosimilars	Similar targeting, different sequences	2012	Potentially challenging 7,141,593 scope

Regulatory and Patent Term Considerations

Patent lifecycle management relies on timely filings and extensions.
Biosimilar developers have challenged patent scope on secondary patents, often focusing on sequence differences or methods of manufacturing.

Comparison with Similar Anti-CD20 Patents

Patent	Applicant	Sequence Claims	Claim Scope	Expiration
US 7,141,593	Genentech	Specific VH and VL sequences	Narrow, sequence-specific	2018 (approximate)
US 6,914,126	Genentech	MAbs with similar functions	Broader, functional	2019 (approximate)
WO 02031589	Celltech	Humanized antibodies	Methods & compositions	2014 (application, patent likely granted)

Implications

The narrow sequence claims limit the scope but protect core antibody features.
Broader functional claims could be contested based on overlaps with other patents.

FAQs

1. How does patent 7,141,593 differ from other anti-CD20 patents?

It primarily claims specific amino acid sequences of the variable regions, providing narrow but strong protection around the particular antibody sequences. Other patents may cover broader functional aspects or different sequences, potentially overlapping with similar antibodies but with varying scope.

2. Can biosimilar developers design around this patent?

Potentially yes, by creating antibodies with significant sequence differences in the variable regions or different functional properties that do not infringe the specific claims. However, proximity in sequence or function can lead to patent challenges.

3. When does the patent expiration date likely occur?

Assuming no extensions, it would have expired around August 28, 2018. Some adjustments, including patent term extensions, could push this date further, which requires evaluation of patent office records.

4. Are there known litigations involving this patent?

No publicly recorded litigations explicitly cite US 7,141,593 post-grant, although patent landscape analyses suggest defensive positioning and potential licensing negotiations.

5. How important are the claim sequences for infringement analysis?

Extremely. Because the claims specify unique amino acid sequences, infringement analysis hinges on whether an antibody's variable regions match these sequences or functionally equivalent variants.

Conclusion: Key Takeaways

Patent Scope & Claims: US 7,141,593 protects specific antibody variable region sequences targeting CD20, with claims focused on both structural and functional features. Narrow claims limit broad infringement but offer precise protection for the sequences.
Patent Landscape: The patent applications and disclosures post-2008 extend to similar antibodies and biosimilar candidates, highlighting ongoing innovation and legal considerations.
Strategic Implications: Developers seeking biosimilar or generic versions must design antibodies with significant sequence divergence or functional differences to avoid infringement.
Legal and Regulatory Considerations: Patent expiry, extensions, and potential legal challenges influence market exclusivity dynamics.
Research and Development: This patent underscores the importance of detailed sequence characterization in antibody therapeutics and their patent protections.

References

[1] United States Patent and Trademark Office (USPTO). "Patent 7,141,593." Grant date: November 28, 2006.
[2] European Patent Office (EPO). Patent family data and priority details.
[3] FDA Approvals and Public Records. Rituximab (Rituxan) approvals and patent expiry data.
[4] Davies, M., et al. (2007). "Anti-CD20 antibodies for autoimmune diseases and B-cell malignancies." Nature Reviews.
[5] PatentScope, WIPO. Patent family records and related applications.

Note: This report is intended for strategic evaluation and is not legal advice. Consult patent professionals for specific infringement and validity assessments.

Details for Patent: 7,141,593

Summary for Patent: 7,141,593